×

Incyte says EU approves oral treatment for chronic skin disease

By Thomson Reuters Nov 16, 2026 | 3:54 PM

Nov 16 (Reuters) – Incyte said on Monday the European Commission had approved its once-daily oral therapy for a type of chronic skin ​disease.

The drug, Povofortay, chemically known as povorcitinib, ‌was approved for adults with moderate-to-severe hidradenitis suppurativa who have responded inadequately to, or cannot take, anti-tumor necrosis factor therapies.

The approval marks a potential new growth driver for Incyte, ‌as ​it looks to expand beyond ⁠its flagship blood cancer ⁠drug Jakafi and strengthen its immunology and inflammation portfolio.

Povorcitinib is also under review by the US Food and Drug Administration for treating moderate-to-severe hidradenitis ​suppurativa, with a regulatory decision expected in the first quarter of 2027, Incyte said.

Hidradenitis suppurativa ⁠is a chronic inflammatory skin ⁠condition characterized by painful nodules, abscesses ​and scarring that can significantly affect patients’ quality of ​life.

The EU approval was based on data from ‌two late-stage studies, which showed that Povofortay met the main goal of improving symptoms at 12 weeks and delivered durable responses through 54 weeks.

Incyte said ⁠up to 71.4% of patients achieved a key measure of clinical response after 54 weeks of treatment, while ⁠the drug’s safety ‌profile remained consistent with earlier studies.

Povorcitinib ⁠works by blocking JAK1, a protein ​involved ‌in the inflammation that leads to ​painful abscesses ⁠and nodules.

Treatment options for the condition are limited and include mainly injectable drugs.

There are currently three FDA-approved treatments for the condition: AbbVie’s Humira, Novartis’ Cosentyx and UCB’s Bimzelx.

(Reporting by Siddhi Mahatole in Bengaluru; Editing by ​Shinjini Ganguli)